The clinical and histopathological effects of combined chemotherapy using cisplatin and peplomycin to treat cancer of the tongue.

Combined chemotherapy (PP therapy) using cisplatin (CDDP) and peplomycin (PEP) was performed as induction chemotherapy for 31 patients with cancer of the tongue, and the clinical and histopathological effects were investigated. As the primary clinical effect, complete response (CR) was observed in three cases, partial response (PR) in 20 cases, minor response (MR) in six cases and no change (NC) in two cases, with a clinical response rate of 74.2%. The histopathological effects of the chemotherapy in the following cases showed these histological Grades: 0 or I in four cases, IIa in 12 cases, IIb in eight cases, III in six cases and IV in one case. Fifteen of the 31 patients who received PP therapy showed a histological Grade of IIb or better, representing 48.4% of the histopathological response rate. With regard to the mode of invasion of the tumor, the histopathological response rate was 90.0% in patients with invasive Grades 1 and 2, 41.7% in those with invasive Grade 3 and 16.7% in those with invasive Grade 4C. There were no patients with invasive Grade 4D in whom the therapy was histopathologically effective. In other words, the histopathological effect significantly decreased as the invasive Grade increased. With regard to the relationship between clinical effects and histopathological effects, there was one CR patient who showed a histological Grade of IIa. Thus, it is noteworthy that clinical effects were not necessarily consistent with post-chemotherapeutic histopathological effects.

[1]  I. Tohnai,et al.  [Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district]. , 1990, Nihon Gan Chiryo Gakkai shi.

[2]  T. Kaneda,et al.  [Primary clinical effects of chemotherapy mainly with cisplatin, peplomycin (PP therapy) against head and neck cancer--the multi-institutional joint research in Tokai district]. , 1987, Nihon Gan Chiryo Gakkai shi.

[3]  M. Hirano,et al.  [Histological effects of cis-platinum-peplomycin induction chemotherapy for head and neck carcinomas]. , 1985, Nihon Gan Chiryo Gakkai shi.

[4]  S. Mashino.  [Effect of the combination of cisplatin and peplomycin on Ehrlich ascites carcinoma and on head and neck squamous cell carcinoma transplanted to nude mice]. , 1985, Nihon Jibiinkoka Gakkai kaiho.

[5]  N. Okada,et al.  [A clinical and histopathological study of anticancer effect of treatment with bleomycin alone--with particular reference to histological disappearance of primary lesion]. , 1985, Nihon Gan Chiryo Gakkai shi.

[6]  A. Matsuda,et al.  [Experimental studies on combination chemotherapy of cisplatin with peplomycin against human squamous cell carcinomas in nude mice]. , 1985, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  H. Hiratsuka,et al.  Mode of invasion, bleomycin sensitivity, and clinical course in squamous cell carcinoma of the oral cavity , 1983, Cancer.

[8]  R. Diasio,et al.  cis-Platinum in gynecologic cancer , 1981 .

[9]  R. Weichselbaum,et al.  Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM). , 1981, Cancer treatment reports.

[10]  C. Merrin.  Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients. , 1979, Cancer treatment reports.

[11]  R. Wittes,et al.  CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck. , 1977, Cancer treatment reports.

[12]  Coltman Ca,et al.  Phase II evaluation of cis-diamminedichloroplatinum(II) in lung cancer. , 1976 .

[13]  C. Coltman,et al.  Phase II evaluation of cis-diamminedichloroplatinum(II) in lung cancer. , 1976, Cancer treatment reports.

[14]  E. Wiltshaw,et al.  Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. , 1976, Cancer treatment reports.

[15]  R. Wittes,et al.  Combination Chemotherapy with cis-Diamminedichloroplatinum (II) and Bleomycin in Tumors of the Head and Neck , 1975 .

[16]  L. Helson,et al.  Clinical trials of cis-diamminedichloroplatinum (NSC-119875). , 1973, Cancer chemotherapy reports.

[17]  Y. Shimosato,et al.  Histological Evaluation of Effects of Radiotherapy and Chemotherapy for carcinomas , 1971 .

[18]  BARNETT ROSENBERG,et al.  Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode , 1965, Nature.